Ocugen (OCGN) Projected to Post Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is expected to post its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect Ocugen to post earnings of ($0.05) per share and revenue of $0.30 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Ocugen Stock Down 7.2 %

Shares of NASDAQ:OCGN opened at $0.61 on Tuesday. Ocugen has a 1 year low of $0.60 and a 1 year high of $2.11. The company has a market capitalization of $176.28 million, a PE ratio of -3.36 and a beta of 3.82. The business has a fifty day moving average price of $0.74 and a two-hundred day moving average price of $0.92. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58.

Analyst Ratings Changes

Several equities analysts recently weighed in on OCGN shares. Chardan Capital restated a “buy” rating and set a $6.00 price target on shares of Ocugen in a research report on Thursday, February 13th. HC Wainwright increased their target price on shares of Ocugen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, February 13th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.